Since then, the results of the CheckMate-227 clinical trial have shown that regardless of the PD-L1 expression status of NSCLC patients with a high TMB (≥10 mutations/Mb), the combination of nivolumab and ipilimumab as a first-line treatment significantly prolongs the patient’s PFS [96]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.